These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6117450)

  • 21. [Biotransformation of drugs].
    Lechat P
    Farmaco Sci; 1972 Mar; 27(3):240-56. PubMed ID: 4623305
    [No Abstract]   [Full Text] [Related]  

  • 22. Species differences in the biotransformation of the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by hepatic microsomes and cytosols from humans, rats, and mice.
    Lin DX; Lang NP; Kadlubar FF
    Drug Metab Dispos; 1995 Apr; 23(4):518-24. PubMed ID: 7600922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drugs and the organism--introduction to pharmacokinetics and biotransformation].
    Pfeifer S; Borchert HH
    Pharmazie; 1978; 33(2-3):128-74. PubMed ID: 674304
    [No Abstract]   [Full Text] [Related]  

  • 24. [Drug metabolism in liver diseases].
    Paumgartner G
    Z Gastroenterol Verh; 1979; 16():42-7. PubMed ID: 95370
    [No Abstract]   [Full Text] [Related]  

  • 25. Metabolism and activation of 1,1-dimethylhydrazine and methylhydrazine, two products of nitrosodimethylamine reductive biotransformation, in rats.
    Godoy HM; Díaz Gómez MI; Castro JA
    J Natl Cancer Inst; 1983 Nov; 71(5):1047-51. PubMed ID: 6580481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism of the A(1)1 adenosine receptor positron emission tomography ligand [18F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([18F]CPFPX) in rodents and humans.
    Bier D; Holschbach MH; Wutz W; Olsson RA; Coenen HH
    Drug Metab Dispos; 2006 Apr; 34(4):570-6. PubMed ID: 16415116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid.
    Wang YP; Yan J; Fu PP; Chou MW
    Toxicol Lett; 2005 Mar; 155(3):411-20. PubMed ID: 15649625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs.
    Andersson SH; Lindgren A; Postlind H
    Drug Metab Dispos; 1998 Jun; 26(6):528-35. PubMed ID: 9616187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro drug metabolism using liver microsomes.
    Hill JR
    Curr Protoc Pharmacol; 2004 Feb; Chapter 7():Unit7.8. PubMed ID: 21956813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proceedings: Quantitative investigations of drug hydroxylating enzymes of the liver using model substrates.
    Dünges W; Heinemann H
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R17. PubMed ID: 4276536
    [No Abstract]   [Full Text] [Related]  

  • 31. The oxidation of ebselen metabolites to thiol oxidants catalyzed by liver microsomes and perfused rat liver.
    Akerboom TP; Sies H; Ziegler DM
    Arch Biochem Biophys; 1995 Jan; 316(1):220-6. PubMed ID: 7840620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biotransformation of drugs by the liver].
    González Macias JG
    Rev Clin Esp; 1974 Nov; 135(3):207-18. PubMed ID: 4615350
    [No Abstract]   [Full Text] [Related]  

  • 33. Rapid liquid chromatography with tandem mass spectrometry-based screening procedures for studies on the biotransformation of drug candidates.
    Fernández-Metzler CL; Owens KG; Baillie TA; King RC
    Drug Metab Dispos; 1999 Jan; 27(1):32-40. PubMed ID: 10068285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug metabolism.
    Cohn VH
    Adv Biol Skin; 1972; 12():81-94. PubMed ID: 4579209
    [No Abstract]   [Full Text] [Related]  

  • 35. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
    Masubuchi N; Makino C; Murayama N
    Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer.
    Shou WZ; Magis L; Li AC; Naidong W; Bryant MS
    J Mass Spectrom; 2005 Oct; 40(10):1347-56. PubMed ID: 16206149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The characterization of an inhibitory complex formed with cytochrome P-450 and a metabolite of 1,1-disubstituted hydrazines.
    Hines RN; Prough RA
    J Pharmacol Exp Ther; 1980 Jul; 214(1):80-6. PubMed ID: 7391974
    [No Abstract]   [Full Text] [Related]  

  • 38. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
    Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
    Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective metabolism of E-3,4-bis(4-ethylphenyl)hex-3-ene in rat liver microsomes.
    Fabian EJ; Metzler M
    Arch Toxicol; 2006 Jan; 80(1):17-26. PubMed ID: 16187102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of drug-metabolizing activities in lyophilized liver and lung microsomal preparations.
    Patel JM; Ortiz E; Shiverick KT; Leibman K
    Drug Metab Dispos; 1983; 11(6):620-1. PubMed ID: 6140152
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.